Treatment of Recurrent Urinary Tract Infection Symptoms with Urinary Antiseptics Containing Methenamine and Methylene Blue: Analysis of Etiology and Treatment Outcomes (2020)

Peer-Reviewed Study · Gama CRB, Pombo MAG, Nunes CP, et al. · December 15, 2020

Gama CRB et al., 2020-12-15: Randomized trial of two methenamine-methylene blue urinary antiseptic combinations in recurrent cystitis, finding both reduced symptoms after three days alongside antibiotics. The paper describes MB's urinary antiseptic action as symptomatic, and both arms also received culture-directed antibiotics.

Methylthioninium hydrochloride, also known as methylene blue, is a thiazine dye related to the monoamine oxidase inhibitor group that exhibits urinary antiseptic action upon oral administration following reduction to leukomethylene blue.

Gama CRB et al., 2020-12-15: Randomized trial of two methenamine-methylene blue urinary antiseptic combinations in recurrent cystitis, finding both reduced symptoms after three days alongside antibiotics. The paper describes MB's urinary antiseptic action as symptomatic, and both arms also received culture-directed antibiotics. Study type: prospective, double-blind, randomized, double-dummy trial. N=288 randomized (144 per group), 272 completed. Country: Brazil. Group A methenamine 120 mg + methylene blue 20 mg; Group B acriflavine 15 mg + methenamine 250 mg + methylene blue 20 mg + Atropa belladonna 15 mg; oral, 3 days, then 3 days with antibiotics. Funding: not stated in record. Conflicts: not stated in record. Comparator: active comparator (the two combinations), plus antibiotics in both arms. Primary endpoint: UTISA urinary regularity improvement 69.4% vs 72.2% (p=0.87). Quote is from the PMC full text introduction, not the abstract. Also filed as MTL-081 (claims C5, C7). Study type: randomized trial.